These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 3134813)

  • 21. Plasmin inhibitors in different fibrinolytic treatment patterns.
    Lasierra J; Diez M; Perera C; Viladés E
    Haemostasis; 1981; 10(1):51-62. PubMed ID: 6162721
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Blood coagulation shifts in patients with myocardial infarction treated with streptokinase].
    Smirnov AA; Dorogun BN; Dobrovol'skiĭ AB; Titaeva EV; Pomerantsev EV
    Kardiologiia; 1988 Nov; 28(11):40-6. PubMed ID: 3068400
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biochemical changes noted during intermittent administration of streptokinase.
    Verstraete M; Vermylen J; Schetz J
    Thromb Haemost; 1978 Feb; 39(1):61-8. PubMed ID: 148118
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [New thrombolytic agents in myocardial infarction].
    Charbonnier B; Lang M; Brochier M
    Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasminogen depletion during streptokinase treatment or two-chain urokinase incubation correlates with decreased clot lysability ex vivo and in vitro.
    Onundarson PT; Haraldsson HM; Bergmann L; Francis CW; Marder VJ
    Thromb Haemost; 1993 Dec; 70(6):998-1004. PubMed ID: 8165625
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nephelometric determination of plasminogen and plasmin inhibitors in human plasma using fibrin suspension as a substrate.
    Saito Y; Takabayashi K; Tsukada T; Inada Y
    Thromb Res; 1983 Apr; 30(1):47-54. PubMed ID: 6222510
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions.
    Wu JH; Diamond SL
    Thromb Haemost; 1995 Aug; 74(2):711-7. PubMed ID: 8585011
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitation of fragment X formation during thrombolytic therapy with streptokinase and tissue plasminogen activator.
    Owen J; Friedman KD; Grossman BA; Wilkins C; Berke AD; Powers ER
    J Clin Invest; 1987 Jun; 79(6):1642-7. PubMed ID: 2953761
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [t-PA in thrombolytic therapy of acute myocardial infarct].
    Rutsch W; Schmutzler H
    Herz; 1994 Dec; 19(6):336-52. PubMed ID: 7843690
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fibrinogen concentration and coronary artery reperfusion after intravenous anisoylated plasminogen streptokinase activator complex or intracoronary streptokinase therapy.
    Marder VJ; Kinsella PA; Brown MJ
    Drugs; 1987; 33 Suppl 3():237-41. PubMed ID: 3315601
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Thrombolytic drugs in acute myocardial infarct].
    Ambrosioni E; Degli Esposti D
    Cardiologia; 1991 Dec; 36(12 Suppl 1):395-402. PubMed ID: 1841796
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dose-ranging studies of anisoylated plasminogen streptokinase activator complex. Studies in healthy volunteers and in patients with acute myocardial infarction.
    Marder VJ; Rothbard RL; Fitzpatrick PG; Francis CW; Norry EC
    Drugs; 1987; 33 Suppl 3():124-32. PubMed ID: 3315577
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Serial changes in hemostatic molecular markers after urokinase therapy of acute myocardial infarction].
    Goto S; Kawai Y; Watanabe K; Hori S; Abe S; Handa S; Ikeda Y
    Kokyu To Junkan; 1992 Jan; 40(1):89-95. PubMed ID: 1532665
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A systemic non-lytic state and local thrombolytic failure of anistreplase (anisoylated plasminogen streptokinase activator complex, APSAC) in acute myocardial infarction.
    Brügemann J; van der Meer J; Takens BH; Hillege H; Lie KI
    Br Heart J; 1990 Dec; 64(6):355-8. PubMed ID: 2271340
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An enzyme-linked immunosorbent assay (ELISA) for the measurement of plasmin-alpha 2-antiplasmin complex in human plasma--application to the detection of in vivo activation of the fibrinolytic system.
    Holvoet P; de Boer A; Verstreken M; Collen D
    Thromb Haemost; 1986 Oct; 56(2):124-7. PubMed ID: 2433784
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fibrin-specific thrombolytic agents.
    Collen D
    Schweiz Med Wochenschr; 1987 Nov; 117(46):1791-8. PubMed ID: 3122317
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-dose systemic streptokinase and acylated streptokinase-plasminogen complex (BRL 26921) in acute myocardial infarction: alterations of the fibrinolytic system and clearance of fibrinolytic activity.
    Köhler M; Hellstern P; Doenecke P; Schwerdt H; Ozbek C; Miyashita C; Winter R; von Blohn G; Bette L; Wenzel E
    Haemostasis; 1987; 17(1-2):32-9. PubMed ID: 3297942
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Thrombolytic therapy with ultra-high doses of streptokinase].
    Köhler M; Doenecke P; Hellstern P; Schwerdt H; Winter R; Ozbek C; Scheffler P; Knobloch W; von Blohm G; Keller HE
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(1-2):62-74. PubMed ID: 2427417
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro effects of the acylated streptokinase-plasminogen activator complex BRL 33 575 incubated with normal human plasma.
    Lämmle B; Noll G; Tran TH; Lohri A; Duckert F
    Thromb Haemost; 1984 Jul; 51(3):403-5. PubMed ID: 6548585
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anisoylated plasminogen streptokinase activator complex (APSAC). A review of its mechanism of action, clinical pharmacology and therapeutic use in acute myocardial infarction.
    Monk JP; Heel RC
    Drugs; 1987 Jul; 34(1):25-49. PubMed ID: 3308411
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.